VJOncology is committed to improving our service to you

ESMO 2018 | Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamide

VJOncology is committed to improving our service to you

Alison Birtle

Alison Birtle, MD, of Royal Preston Hospital Lancashire Teaching Hospitals, Preston, UK, discusses the sequencing of drugs in metastatic castration-resistant prostate cancer. Excitingly, the first prospective study to assess sequencing in this disease space (NCT02254785) was presented on the first day of at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany (Kim Chi, et al.). Dr Birtle discusses the sequencing of cabazitaxel, abiraterone or enzalutamide in this study, and highlights the promising data that was reported for the study endpoints.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter